ADMA Biologics, Inc. (NASDAQ:ADMA) Position Increased by Mackenzie Financial Corp

Mackenzie Financial Corp boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 212.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,539 shares of the biotechnology company's stock after purchasing an additional 50,660 shares during the period. Mackenzie Financial Corp's holdings in ADMA Biologics were worth $1,278,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Barclays PLC grew its position in ADMA Biologics by 192.2% in the third quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock valued at $10,567,000 after acquiring an additional 347,692 shares in the last quarter. KBC Group NV boosted its stake in shares of ADMA Biologics by 53.6% in the fourth quarter. KBC Group NV now owns 10,063 shares of the biotechnology company's stock valued at $173,000 after purchasing an additional 3,513 shares during the period. Heck Capital Advisors LLC acquired a new stake in ADMA Biologics during the 4th quarter valued at $225,000. Ausbil Investment Management Ltd purchased a new stake in ADMA Biologics during the 4th quarter worth $150,000. Finally, New Millennium Group LLC lifted its holdings in ADMA Biologics by 3.5% in the 4th quarter. New Millennium Group LLC now owns 214,309 shares of the biotechnology company's stock worth $3,675,000 after buying an additional 7,246 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Up 3.0%

ADMA stock traded up $0.59 during mid-day trading on Monday, hitting $20.43. 2,162,510 shares of the company were exchanged, compared to its average volume of 3,694,347. The firm has a fifty day simple moving average of $20.65 and a 200 day simple moving average of $18.84. The company has a market capitalization of $4.88 billion, a PE ratio of 72.96 and a beta of 0.57. ADMA Biologics, Inc. has a twelve month low of $9.63 and a twelve month high of $25.67. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same quarter last year, the business posted $0.08 earnings per share. The firm's revenue for the quarter was up 40.2% on a year-over-year basis. On average, research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lawrence P. Guiheen sold 7,779 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total value of $158,069.28. Following the transaction, the director now directly owns 114,830 shares in the company, valued at approximately $2,333,345.60. This trade represents a 6.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

ADMA has been the subject of several recent analyst reports. Raymond James raised their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ADMA Biologics currently has an average rating of "Moderate Buy" and a consensus price target of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.